Company Filing History:
Years Active: 2008
Title: David Priestman: Innovator in Therapeutic Compositions
Introduction
David Priestman is a notable inventor based in Oxford, GB. He has made significant contributions to the field of therapeutic compositions, particularly in the treatment of glycolipid storage-related disorders. His innovative approach has the potential to impact many lives affected by these conditions.
Latest Patents
David Priestman holds a patent for "Therapeutic compositions and methods of treating glycolipid storage related disorders." This patent describes a method for treating glycolipid storage-related disorders by administering a therapeutically effective amount of an inhibitor of glycolipid synthesis. This method can be combined with an agent that increases the rate of glycolipid degradation or with bone marrow transplantation. The inhibitors of glycolipid synthesis mentioned in his patent include N-butyldeoxynojirimycin (NB-DNJ), N-butyldeoxygalactonojirimycin (NB-DGJ), and N-nonyldeoxynojirimycin (NN-DNJ). The disorders addressed by this patent include Gaucher disease, Sandhoff's disease, Fabry's disease, Tay-Sach's disease, Niemann-Pick C storage disease, GM1 gangliosidosis, and other genetic disorders where neuronal glycolipid accumulation contributes to disease pathology. He has 1 patent to his name.
Career Highlights
David Priestman is associated with Actelion Pharmaceuticals Ltd., where he continues to work on innovative solutions for complex medical conditions. His expertise in therapeutic compositions has positioned him as a valuable asset in the pharmaceutical industry.
Collaborations
Some of his notable coworkers include Raymond A Dwek and Terence D Butters. Their collaborative efforts contribute to advancing research in the field of glycolipid storage disorders.
Conclusion
David Priestman's work in therapeutic compositions showcases his dedication to addressing significant medical challenges. His innovative methods and collaborations highlight the importance of research in improving treatment options for patients with glycolipid storage-related disorders.